Download PDF
Z Geburtshilfe Neonatol 2001; 205(4): 128-136
DOI: 10.1055/s-2001-16821
ÜBERSICHT

Georg Thieme Verlag Stuttgart · New York

Der Einfluss thrombophiler Faktoren auf thromboembolische und andere Schwangerschaftskomplikationen[1]

The influence of thrombophilic factors on the incidence of deep vein thrombosis and pregnancy complicationsL. Heilmann1 , F.-G. v. Tempelhoff1 , S. Gerhold1 , W. Rath2
  • 1 Abt. Gynäkologie und Geburtshilfe, Stadtkrankenhaus Rüsselsheim
  • 2 Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum der RWTH Aachen
Further Information

Publication History

Publication Date:
28 August 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Thromboserisiko in der Schwangerschaft ist um das 4,2fache erhöht, wobei die lnzidenz zwischen 0,05 und 0,1 % liegt. Angeborene und erworbene thrombophile Faktoren spielen bei ca. 50 % der Schwangeren mit venöser Thrombose eine Rolle und können gleichzeitig mit dem Auftreten wiederholter Spontanaborte, eines intrauterinen Fruchttodes und der frühen schweren Präeklampsie in Verbindung stehen.Zum gegenwärtigen Zeitpunkt gibt es keine generelle Übereinstimmung darüber, alle Schwangeren mit thrombophilen Risiken einer antithrombotisch-medikamentösen Prophylaxe zuzuführen. Auf alle Fälle sollte bei anamnestischen Hinweisen auf eine tiefe Beinvenenthrombose, auf einen wiederholten Spontanabort, auf eine schwere Präeklampsie einschließlich HELLP-Syndrom, bei Patientinnen mit intrauterinem Fruchttod unklarer Ursache und bei schwerer Plazentainsuffizienz eine Untersuchung der thrombophilen Faktoren durchgeführt werden. Als präventive Maßnahmen stehen die niedermolekularen Heparine allein oder in Kombination mit low-dose-Azetylsalizylsäure (ASS, Aspirin®) zur Verfügung.

Pulmonary embolism and/or deep vein thrombosis are a major cause of maternal mortality. In a number of adverse pregnancy outcome including preeclampsia, recurrent spontaneous abortion, restricted fetal growth and fetal death a role for thrombophilia (acquired and hereditable) has been postulated. Monitoring of acquired factors such as antiphospholipid-antibodies and hereditable factors (factor V Leiden, prothrombin mutation) may help predict the occurrence of pregnancy complications.Low molecular weight heparins (LMWH), since their introduction well established during pregnancy, and the rate of adverse fetal outcomes are related to co-morbidity maternal conditions rather than to the treatment itself. The use of LMWH is recommended for all moderate risk and high-risk pregnant patients.

Schlüsselwörter

Schwangerschaft - Thrombophilie - Thrombose - Präeklampsie - wiederholter Abort

Key words

Pregnancy - thrombophilia - deep vein thrombosis - preeclampsia - recurrent abortion

1 Eingang: 19. 2. 2001
Angenommen nach Revision: 29. 3. 2001

Literatur

1 Eingang: 19. 2. 2001
Angenommen nach Revision: 29. 3. 2001

  • 01 Backos  M, Chilcott  I, Ray  R, Reagan  L. Pregnancy complications in women with recurrent miscarriage and antiphospholipid antibodies treated with aspirin and heparin.  Hum Reprod. 1997;;  12 61
    Google Scholar
  • 02 Balasch  J, Reverater  J C, Fabregues  F, Tassies  D, Rafel  M, Crens  M, Vanrell  J A. First trimester repeated abortion is not associated with activated protein C resistance.  Human Reprod. 1997;;  12 1094-1097
    Google Scholar
  • 03 Bick  R L. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects.  Haemat/Oncol Clin North America. 2000;;  14 1117-1131
    Google Scholar
  • 04 Birsdall  M, Pattison  N, Chamley  L. Antiphospholipid antibodies in pregnancy.  Aust NZ J Obstet Gynec. 1992;;  32 328
    Google Scholar
  • 05 Bockarewa  M I, Bremme  K, Blombäck  M. Arg 506-GLn mutation in factor V and risk of thrombosis during pregnancy.  Br J Haematol. 1996;;  92 473-478
    Google Scholar
  • 06 Branch  D W, Silver  R M, Blackwell  J L et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.  Obstet Gynecol. 1992;;  80 614-620
    Google Scholar
  • 07 Brenner  B, Sarig  G, Weiner  Z, Youmis  J, Blumenfeld  Z, Lanir  N. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause.  Thromb Haemostas. 1999;;  82 6-9
    Google Scholar
  • 08 Christiansen  O B. Epidemiological, immunogenetic and immunotherapeutic aspects of unexplained recurrent miscarriage. Thesis, Kobenhaven; 1997:
    Google Scholar
  • 09 Clark  A L, Branch  D W, Silver  R M, Harris  E N, Pierangeli  S, Spinnato  J A. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.  Obstet Gynecol. 1999;;  93 437-441
    Google Scholar
  • 10 Conard  J, Horellou  M H, van Dreden  P, Lecomte  T, Samama  M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S.  Thromb Haemostas. 1990;;  63 319-320
    PubMedGoogle Scholar
  • 11 Conard  J, Horellou  M H, van Dreden  P, Samama  M. Pregnancy and congenital deficiency in antithrombin m or protein C.  Thromb Haemostas. 1987;;  58 39
    PubMedGoogle Scholar
  • 12 Cook  G, Walker  D, Mc Call  F. Familiar thrombophilia and activated protein C resistance - thrombotic risk in pregnancy?.  Br J Haematol. 1994;;  87 873-875
    PubMedGoogle Scholar
  • 13 Cowchock  S. Treatment of antiphospholipid syndrome in pregnancy.  Lupus. 1998;;  7, Suppl. 2 95-97
    CrossrefPubMedGoogle Scholar
  • 14 De Stefano  V, Mastrangelo  S, Paciaroni  K, Ireland  M, Lane  D A, Scirpa  P, Bizzi  B, Leone  G. Thrombotic risk during pregnancy and puerperium in women with APC resistence - effective subcutaneous heparin prophylaxis in pregnant patients.  Thromb Haemostas. 1995;;  74 793-794
    PubMedGoogle Scholar
  • 15 De Vries  J IP, Dekker  G A, Huijgens  P C. Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.  Br J Obstet Gynaecol. 1997;;  104 1248
    CrossrefPubMedGoogle Scholar
  • 16 Deitcher  S R, Park  V M, Kutteh  W H. Prothrombin 20210G > A mutation analysis in Caucasian women with early first trimester pregnancy loss.  Blood Suppl. 1998;;  1 92
    PubMedGoogle Scholar
  • 17 Dekker  G A, de Vries  J P, Doelitsch  P M, Huijens  P C, von Blomberg  B ME, van Geijn  H P. Underlying disorders associated with severe early onset preeclampsia.  Am J Obstet Gynecol. 1996;;  173 1042
    PubMedGoogle Scholar
  • 18 Department of Health, Welsh Office, Scottish Home and Health Department and Department of Health and Social Service Northern Ireland .Confidential Enquiries into maternal death in the. United Kingdom. London; 1998;: 1994-1997
    Google Scholar
  • 19 DeSwiet  M. Thromboembolic disease. In: High risk pregnancy. James DK, Steer PJ, Weiner CP, Ganik B. Saunders WP; 1999:
    Google Scholar
  • 20 Dilley  A, Hopper  W, Janil  M E, Austin  H, Evatt  R, Philipp  C S. The role of four coagulation genes in thrombosis during pregnancy: Factor V Leiden, Prothrombin 20210, MTHFR, ACE.  Thromb Haemostas. 1999;;  Suppl 1 227
    PubMedGoogle Scholar
  • 21 Dizon-Townson  D S, Nelson  L M, Easton  K, Ward  K. The factor V Leiden mutation may predispose women to severe preeclampsia.  Am J Obstet Gynecol. 1996;;  175 902
    CrossrefPubMedGoogle Scholar
  • 22 Foka  Z J, Lambropoulos  A F, Saravelos  H et al. Factor V Leiden and prothrombin 620210A mutations but not methylentetrahydrofolat reductase C677T are associated with recurrent miscarriage.  Human Reprod. 2000;;  15 458-462
    CrossrefPubMedGoogle Scholar
  • 23 Friederich  P W, Samson  B J, Simioni  P, Zanardi  S, Huisman  M V, Kindt  L, Prandoni  P, Büller  H R, Girolami  A, Prins  M H. Frequency of pregnancy related thromboembolism in anticoagulant factor deficient women: Implications for prophylaxis.  Ann Int Med. 1996;;  125 955-960
    PubMedGoogle Scholar
  • 24 Gerhardt  A, Scharf  R E, Beckmann  M W, Struwe  S, Bender  H G, Pillny  N, Sandmann  W, Zotz  R B. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  New Engl J Med. 2000;;  342 374-380
    CrossrefPubMedGoogle Scholar
  • 25 Gherman  R B, Goodwin  T M, Leung  B, Byrne  J D, Hethumumi  R, Montorro  M. Incidence, clinical characteristics and timing of objectively diagnosed venous thromboembolism during pregnancy.  Obstet Gynec. 1999;;  94 7309-7334
    PubMedGoogle Scholar
  • 26 Ginsberg  J S. Thromboembolism and pregnancy.  Thromb Haemostas. 1999;;  82 620
    PubMedGoogle Scholar
  • 27 Girolami  A, Simioni  P, Girolami  B, Scarano  L. G to A 20210 Prothrombin polymorphism and venous thrombosis: simple association or causal relationship?.  Clin Appl Thromb/Hemost. 2000;;  6 135-138
    PubMedGoogle Scholar
  • 28 Grandone  E, Margaglione  M, Colaizzo  D. Factor V Leiden, C > T MTHFR Polymorphismus and genetic susceptibility to preeclampsia.  Thromb Haemostas. 1997;;  77 1052
    PubMedGoogle Scholar
  • 29 Grandone  E, Margaglione  M, Colaizzo  D. Prothrombotic genetic risk factors and the occurrence of gestational hypertension with or without proteinuria.  Thromb Haemostas. 1999;;  81 349
    PubMedGoogle Scholar
  • 30 Grandone  E, Margaglione  M, Colaizzo  D, Andrea  G D, Cappucci  G, Brancaccio  V, di Minno  G. Genetic susceptibility to pregnancy related to venous thromboembolism: Roles for factor V Leiden, prothrombin G20210A and methylene tetrahydrofolate reductase C677T mutations.  Amer J Obstet Gynec. 1998;;  179 1324-1328
    PubMedGoogle Scholar
  • 31 Grandone  E, Margaglione  M, Colaizzo  D et al. Faktor V Leiden is associated with repeated and recurrent fetal losses.  Thromb Haemost. 1997;;  77 822-824
    PubMedGoogle Scholar
  • 32 Granger  K A, Farquharson  R G. Obstetric outcome in antiphospholipid syndrome.  Lupus. 1997;;  6 509-513
    PubMedGoogle Scholar
  • 33 Greaves  M. Antiphospholipid antibodies and thrombosis.  Lancet. 1999;;  353 1348-1353
    CrossrefPubMedGoogle Scholar
  • 34 Greer  I A, de Swiet  M. Thrombosis prophylaxis in obstetric and gynecology.  Br J Obstet Gynecol. 1993;;  100 37
    PubMedGoogle Scholar
  • 35 Greer  I A. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynecology.  Bailliers Clin Obstet Gynecol. 1997;;  11 403-430
    PubMedGoogle Scholar
  • 36 Greer  I A. Thrombosis in pregnancy: malemal and fetal issues.  Lancet. 1999;;  353 1258-1265
    CrossrefPubMedGoogle Scholar
  • 37 Hallak  M, Senderowicz  J, Cassel  A, Shapira  Ch, Agkai  E, Auslender  R, Abramovici  H. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.  Am J Obstet Gynecol. 1997;;  176 889-893
    PubMedGoogle Scholar
  • 38 Heilmann  L, Schneider  D M, v Tempelhoff  G F, Kuse  S. Antiphospholipid-antibodies and other thrombophilic defects in patients with a history of early onset severe preeclampsia or HELLP-syndrome.  Geburtsh u Frauenheilk. 1999;;  59 95-100
    PubMedGoogle Scholar
  • 39 Heilmann  L, Schneider  D M, von Tempelhoff  G F. Antithrombotic therapy in high risk pregnancy.  Hemat/Oncol Clin North America. 2000;;  14 1133-1150
    PubMedGoogle Scholar
  • 40 Heinrich  F. Venenthrombosen und Lungenembolien in der Schwangerschaft und im Wochenbett.  Med Welt. 2000;;  51 (Suppl 1) 1-32
    PubMedGoogle Scholar
  • 41 Hellgren  M, Svensson  P J, Dahlbäck  B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.  Am J Obstet Gynecol. 1995;;  173 210-213
    CrossrefPubMedGoogle Scholar
  • 42 Hellgren  M, Tengborn  L, Abildgaard  U. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin.  Gynecol Obstet Invest. 1982;;  13 76-89
    PubMedGoogle Scholar
  • 43 Hirsch  D R, Mikkola  K M, Marks  P W, Fox  E A, Dorfman  D M, Evenstein  B M, Goldhaber  S Z. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use. Prevalence of factor V Leiden.  Am Heart J. 1996;;  131 1145-1148
    CrossrefPubMedGoogle Scholar
  • 44 Holmes  Z, Packos  M, Atoyebi  W, Pickering  W, Regan  L, Cohen  H. Screening for heritable thrombophilic risk factors in a recurrent miscarriage population.  Thromb Haemostas. 1999;;  Suppl 534
    PubMedGoogle Scholar
  • 45 Katano  K, Aoki  K, Sasa  H, Ogasawara  M, Matsuura  E, Yagami  Y. β2-Glycoprotein I-dependent anticardiolipid antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women.  Human Reproduction. 1996;;  11 509-512
    PubMedGoogle Scholar
  • 46 Khamashta  M A. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome.  Lupus. 1998;;  7, Suppl 2 62-65
    PubMedGoogle Scholar
  • 47 Kornberg  A, Raziel  A, Rahimini-Levene  N, Yono  R, Sela  B A, Ron-El  R. Hypercoagulability and recurrent abortion.  Blood. 1998;;  92, Suppl 1 121b
    PubMedGoogle Scholar
  • 48 Krauss  Th, Augustin  H G, Osmers  R, Meden  H, Unterhalt  M, Kuhn  W. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelet syndrome.  Obstet Gynecol. 1998;;  92 457
    CrossrefPubMedGoogle Scholar
  • 49 Krnic-Barrie  S, O'Connor  C R, Looney  S W et al. A retrospective review of 61 patients with antiphospholipid syndrome.  Arch Intern Med. 1997;;  157 2101
    CrossrefPubMedGoogle Scholar
  • 50 Kupferminc  M J, Eldor  A, Steinman  N. Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med. 1999;;  340 9
    CrossrefPubMedGoogle Scholar
  • 51 Kutteh  W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low dose aspirin is superior to low dose aspirin alone.  Am J Obstet Gynecol. 1996;;  174 1584-1589
    CrossrefPubMedGoogle Scholar
  • 52 Kutteh  W H, Park  V M, Deitcher  St R. Hypercoagulable stete mutation analysis in white patients with early first trimester recurrent pregnancy loss.  Fert Steril. 1999;;  71 1048-1053
    PubMedGoogle Scholar
  • 53 Landy  H J, Kessler  C, Kelly  W K, Weingold  A B. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipid antibodies.  Am J of Perinatology. 1992;;  9 146-151
    PubMedGoogle Scholar
  • 54 Laskin  C A, Bombardier  C, Hannah  M E, Mandel  F P, Ritchie  J WK, Farewell  V, Farine  D, Spitzer  K, Fielding  L, Soloninka  C A, Yeung  M. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.  N Engl J Med. 1997;;  337 148-153
    CrossrefPubMedGoogle Scholar
  • 55 Lima  F, Khamashta  M A, Buchanan  N MM. A study of sixty pregnancies in patients with the antiphospholipid syndrome.  Clin Exp Rheum. 1996;;  14 131
    PubMedGoogle Scholar
  • 56 Lindoff  C, Ingemarson  I, Martinsson  G, Segelmark  M, Thysell  H, Astedt  B. Preeclampsia is associated with reduced response to activated protein C.  Am J Obstet Gynecol. 1997;;  176 457
    PubMedGoogle Scholar
  • 57 Linqvist  P. Risk estimation and prediction of preeclampsia, IUGR, and thrombosis in pregnancy. Thesis, Malmö; 1999:
    Google Scholar
  • 58 Lockshin  M D, Druzin  M L, Qamar  T. Prednison does not prevent recurrent fetal death in women with antiphospholipid antibody.  Am J Obstet. 1989;;  160 439-443
    PubMedGoogle Scholar
  • 59 Lubbe  W F, Liggins  G C. Lupus anticoagulant and pregnancy.  Am J Obstet Gynecol. 1985;;  153 322
    PubMedGoogle Scholar
  • 60 Lynch  A, Marlar  R, Muurphy  J, Davila  G, Santos  M, Rutledge  J, Emlen  W. Antiphospholipid antibodies in predicting adverse pregnancy outcome.  Ann Intern Med. 1994;;  120 470-475
    PubMedGoogle Scholar
  • 61 Macklon  N S, Greer  I A. Venous thrombembolic diseaese in obstetrics and gynaecology. The Scottish experience.  Scot Med J. 1996;;  41 83-86
    PubMedGoogle Scholar
  • 62 McColl  N D, Ramsay  J, Tait  R, Walker  J D, McCall  F, Conkie  J A, Carty  M I, Greer  I A. Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemostas. 1997;;  78 1183-1188
    PubMedGoogle Scholar
  • 63 Mello  G, Parretti  E, Martini  E et al. Usefulness of screening for congenital or acquired hemostasis abnormalities in women with previous complicated pregnancies.  Hemostasis. 1999;;  29 197-203
    PubMedGoogle Scholar
  • 64 Metz  J, Kloss  M, Molley  C JO et al. Prevalence of FVL is not increased in women with recurrent miscarriage.  Clin Appl Thromb/Hemost. 1997;;  3 137-140
    PubMedGoogle Scholar
  • 65 Mimuro  S, Lahoud  R, Beutler  L, Trudinger  B. Changes of resistance to activated protein C in the course of pregnancy and prevalence of factor V mutation.  Aust NZ J Obstet Gynaecol. 1998;;  38 200-204
    PubMedGoogle Scholar
  • 66 Murphy  R P, Donoghue  C, Nallen  R J et al. Prospective evaluation of the risk conferred by FVL and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy.  Arterioscler Thromb Vasc Biol. 2000;;  20 266-270
    PubMedGoogle Scholar
  • 67 Nenfeld  M, Koch  H G, Auberger  K, Schobess  R, Bäumer  R, Kaise  M, Reinkemeier  A, Theilling  B, Junker  R. The PAI-1 4G/4G genotype is a risk factor for venous thrombosis carriers of the FVG1691A mutation.  Ann Hematology. 2000;;  79, Suppl I 33
    PubMedGoogle Scholar
  • 68 Öhlin  A K, Norlund  L, Marlar  R A. Thrombomodulin gene variations and thromboembolic disease.  Thromb Haemostas. 1997;;  78 396
    PubMedGoogle Scholar
  • 69 Out  H J, Bruinse  H W, Christiaens  G CML, vanVliet  M, deGroot  P G, Nieuwenhuis  H K, Derksen  R HWM. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies.  Am J Obstet Gynecol. 1992;;  167 26-32
    PubMedGoogle Scholar
  • 70 Peltier  J Y, de Mazancourt  P, Beaufils  F, Guyot  B, Beumebarek  Y, Doleans  M, Richard  L, de Rancourt  E. Incidence of metabolic and hemostatic variables in 72 women with pregnancy induced hypertension.  Thromb Haemostas. 1999;;  Suppl 534
    PubMedGoogle Scholar
  • 71 Pickering  W, Holmes  Z, Regan  L, Cohen  H. Normal prevalence of the G20210A prothrombin gene mutation in women with recurrent miscarriage.  Br J Haematol. 1998;;  102 250
    PubMedGoogle Scholar
  • 72 Poort  S R, Rosedaal  F R, Reimtsa  P H, Bertina  R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood. 1996;;  88 3698
    CrossrefPubMedGoogle Scholar
  • 73 Preston  F E, Rosendaal  F R, Walter  I D. Increased fetal loss in women with heritable thrombophilia.  Lancet. 1996;;  348 913
    CrossrefPubMedGoogle Scholar
  • 74 Rai  R, Cohen  H, Dave  M, Regan  L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;;  314 253
    CrossrefPubMedGoogle Scholar
  • 75 Rai  R, Regan  L, Hadley  E, Dave  M, Kohen  H. Second trimester pregnancy loss is associated with activated protein C resistance.  Br J Hematol. 1996;;  92 489
    PubMedGoogle Scholar
  • 76 Rand  J H, Wu  X X, Guller  S. Reduction of annexin V (placental anticoagulant protein I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion.  Am J Obstet Gynecol. 1994;;  171 1566
    PubMedGoogle Scholar
  • 77 Rath  W, Heilmann  L. Gerinnungsstörungen in Gynäkologie und Geburtshilfe. Thieme, Stuttgart; 1999:
    Google Scholar
  • 78 Ray  J G, Laskin  C A. Folic acid and homocysteine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: a systematic review.  Placenta. 1999;;  20 519-529
    CrossrefPubMedGoogle Scholar
  • 79 Reece  E A, Gabrielli  S, Cullen  M T et al. Recurrent adverse pregnancy outcome and antiphospholipid antibodies.  Am J Obstet Gynecol. 1990;;  163 162-169
    PubMedGoogle Scholar
  • 80 Reece  E A, Garofalo  J, Zheng  X Z, Assimakopoulos  E. Influence of antiphospholipid antibody titer, prior pregnancy losses and treatment.  J Reprod Med. 1997;;  42 49-55
    PubMedGoogle Scholar
  • 81 Ridker  P M, Miletich  J P, Buring  J E, Ariya  A A, Priel  D T, Manson  J AK, Hill  J A. Factor V Leiden mutation is a risk factor for recurrent pregnancy loss.  Ann Int Med. 1998;;  128 1000
    PubMedGoogle Scholar
  • 82 Rosendaal  F R. Risk factors for venous thrombotic disease.  Thromb Haemostas. 1999;;  82 610-619
    PubMedGoogle Scholar
  • 83 Rutherford  S E, Montero  M, Mc Schee  W. Thromboembolic disease associated with pregnancy: An 11 year review.  Am J Obstet Gynecol. 1991;;  164 286
    PubMedGoogle Scholar
  • 84 Sarig  G, Hoffimann  R, Youmis  J, Lanir  N, Blumenfeld  Z, Brenner  B. Thrombophilia is common in women with pregnancy loss associated with late pregnancy wastage.  Thromb Haemostas. 1999;;  Suppl I 226
    PubMedGoogle Scholar
  • 85 Silver  R N, Draper  M J, Scott  J R et al. Clinical consequences of antiphospholipid antibodies: An historic cohort study.  Obstet Gynecol. 1994;;  83 372
    PubMedGoogle Scholar
  • 86 Spina  V, Alexandri  V, Morini  F. The impact of the factor V Leiden mutation on pregnancy.  Human Reproduction. 2000;;  6 301-306
    PubMedGoogle Scholar
  • 87 Thorarensen  O, Ryan  S, Hunter  J et al. Factor V Leiden mutation and unrecognized cause of hemiplegic cerebral palsy, neonatal stroke and placental thrombosis.  Ann Neurol. 1997;;  42 372-375
    CrossrefPubMedGoogle Scholar
  • 88 Triplett  D A. Obstetrical complications associated with antiphospholipid antibodies.  In: Coulam CB, Faulk WP, McIntyre JA: Immunological Obstetrics. Norton Medical Books; 1992:
    Google Scholar
  • 89 Valennsise  H, Vaquero  E, de Carolis  C, Stipa  E, Perricone  R, Arundini  D, Romanini  C. Normal fetal growth in women with antiphospholipid syndrome treated with high-dose intravenous immunoglobulin (IVIG).  Prenatal Diagnosis. 1995;;  15 509-517
    PubMedGoogle Scholar
  • 90 Vandenbroucke  J P, van der Meer  F JM, Helmerhorst  F M, Rosendaal  F R. Factor V Leiden: should we screen oral contraceptive users and pregnant women?.  Brit Med J. 1996;;  313 1127-1130
    PubMedGoogle Scholar
  • 91 Van Pampus  M G, Dekker  G A, Wolf  H. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia.  Am J Obstet Gynecol. 1999;;  180 1146
    CrossrefPubMedGoogle Scholar
  • 92 Vincente  V, Rodriguez  C, Soto  I, Fernandez  M, Moraleda  J M. Risk of thrombosis during pregnancy and postpartum in hereditary thrombophilia.  Am J Haematol. 1994;;  46 151
    PubMedGoogle Scholar
  • 93 Vollset  S E, Bjorke-Monsen  A AL, Irgens  L M. Plasma total homocysteine and previous pregnancies: the Hordaland Homocysteine Study. Proceedings of the 2nd International Symposium on Homocysteine. Neijmegen, Holland; 1998:
    Google Scholar
  • 94 Walker  I D. Thrombophilia in pregnancy.  J Clin Pathol. 2000;;  53 573-580
    CrossrefPubMedGoogle Scholar
  • 95 Walker  M C, Smith  G M, Perkins  S L. Changes in homocystein levels during normal pregnancy.  Am J Obstet Gynecol. 1999;;  180 660
    PubMedGoogle Scholar
  • 96 Wilson  W A, Gharafi  A E, Koike  T, Lockshin  M, Branch  D W, Piete  J Ch, Brey  R, Derksen  R, Harris  H N, Hughes  G RV, Triplett  D A, Khamashta  M A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome.  Arthr & Rheumat. 1999;;  42 1309-1311
    PubMedGoogle Scholar
  • 97 Wramsby  M, Bremme  K, Lindner  St, Blombäck  M. Prevalence of factor V G1691A mutation and prothrombin 20210A polymorphism in women with habitual abortions.  Thromb Haemostas. 1999;;  Suppl 541
    PubMedGoogle Scholar
  • 98 Yasuda  M, Takakuwa  K, Tokunaga  A, Tanaka  K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.  Obstet Gynecol. 1995;;  86 555-559
    PubMedGoogle Scholar
  • 99 Younis  J S, Brenner  B, Okel  G et al. Activated protein C resistance and FVL mutation can be associated with first as well as second trimester recurrent pregnancy loss.  Am J Reprod. 2000;;  43 31-35
    PubMedGoogle Scholar

Prof. Dr. med. L. Heilmann 

Abteilung Gynäkologie/Geburtshilfe
Stadtkrankenhaus Rüsselsheim

65428 Rüsselsheim

      >